

Molecular structure investigation and biological evaluation of Michael adducts derived from dimedone

Assem Barakat^{1,2} · Abdullah M. Al-Majid¹ ·
Mohammad Shahidul Islam¹ · Ismail Warad³ ·
Vijay H. Masand⁴ · Sammer Yousuf⁵ ·
M. Iqbal Choudhary^{1,5}

Received: 19 March 2015 / Accepted: 29 August 2015 / Published online: 11 September 2015
© Springer Science+Business Media Dordrecht 2015

Abstract Trimolecular salt Michael adducts **2a–c** were synthesized in excellent yields up to 92 % via one-pot multicomponent reactions in an aqueous medium. The chemical structures of compounds **2a–c** were characterized by X-ray single-crystal diffraction techniques. Calculations of the density functional theory for the synthesized compound were performed. The stability of the products was deduced by TGA analysis. Compounds **2a–c** were screened in vitro for different bio-assays such as thymidine phosphorylase inhibition assay, urease inhibition assay, β -glucuronidase inhibition assays and cytotoxicity against PC-3 and HeLa cell lines.

Keywords Michael adduct · Dimedone · Thymidine phosphorylase assay · Urease inhibition assay · β -Glucuronidase inhibition assay

Assem Barakat, Abdullah M. Al-Majid, Mohammad Shahidul Islam, Ismail Warad, Vijay H. Masand, Sammer Yousuf and M. Iqbal Choudhary contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s11164-015-2257-1) contains supplementary material, which is available to authorized users.

✉ Assem Barakat
ambarakat@ksu.edu.sa

¹ Department of Chemistry College of Science, King Saud University, PO Box 2455, Riyadh 11451, Saudi Arabia

² Department of Chemistry, Faculty of Science, Alexandria University, PO Box 426, Ibrahimia, Alexandria 21321, Egypt

³ Department of Chemistry, Science College, Al-Najah National University, PO Box 7, Nablus, Palestine

⁴ Department of Chemistry, Vidya Bharati College, Amravati, Maharashtra 444 602, India

⁵ H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan

Introduction

5,5-Dimethylcyclohexane-1,3-dione, commonly known as dimedone, belongs to the family of cyclic 1,3-diketones –class of organic compounds. A wide range of applications of dimedones includes its use as reagent for various analytical techniques [1, 2], as well as a versatile synthon for synthesis of several *spiro* and heterocyclic compounds [3], such as xanthene derivatives, which have emerged as an important class of compound because of their industrial importance [4] and other synthetic applications [5].

The versatile chemistry [6–10] and ready availability of cyclohexane-1,3-diones [11–13] and its derivatives make them suitable precursors for the preparation of divergent organic compounds, for example chromene derivatives, which possess anticancer, antioxidant, spasmolytic, anti-anaphylactic, anti-HIV and anti-bacterial activities [14, 15], oxazolidinones with antibacterial activity [16–19], substituted xanthene derivatives with several uses in dyes [20, 21], laser technology [22], fluorescent compounds [23], and more importantly, have been reported to show a variety of biological activity [24–26]. Additionally, acridine and its derivatives display antimalarial, anticancer, antibacterial, and mutagenic properties, while phenylbutazones exhibit unique pharmacological uses for pain treatment associated with Tietze's syndrome and rheumatoid arthritis [27].

On the other hand, with the increasing environmental concerns, green chemistry has attracted major scientific and commercial interest in recent years. Multicomponent one-pot reactions are an efficient and economical procedure, with wide uses in the preparation of heterocycles molecules [28–30]. On the other hand, organic transformation takes place in aqueous media gives a clean, environmentally safe, and cost-effective approach. Recently, Barakat and coworkers reported examples for MCR (one-pot fission) for example reaction of substituted cyclohexanedione with alkanal mediated by diethylamine in water [31–36].

In the current study, the structure of salt Michael adducts **2a–c** were elucidated by X-ray single-crystal diffraction and TGA study. In addition, density functional theory (DFT) using B3LYP/6-311G(d,p) method were used to study different structural aspects of the compounds. Also, the synthesized compounds **2a–c** were evaluated for a set of in vitro biochemical assays.

Experimental

General

Chemical reagents were purchased from Fluka, Sigma-Aldrich, Aldrich, etc., and were used without further purification, unless otherwise stated. The crystal data were collected on a Bruker APEX-II CCD area diffractometer, crystallographic data for the compounds, **2a**, **2b** and **2c** are deposited with the CCDC-993141, 993142, and 993140 respectively.

Diethylammonium 2-((4-bromophenyl)(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)methyl)-5,5-dimethyl-3-oxocyclohex-1-enolate (2a)

Compound **2a** was synthesized from dimedone and *p*-bromobenzaldehyde **1a** as a white crystal. The structure of **2a** was unambiguously deduced by X-ray diffraction analysis. A suitable colorless cubic crystal of **2a** was grown in CHCl₃/Et₂O at rt after 48 h.

Diethylammonium 2-((3-bromophenyl)(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)methyl)-5,5-dimethyl-3-oxocyclohex-1-enolate (2b)

Compound **2b** was synthesized from dimedone and *m*-bromobenzaldehyde **1b** as a crystalline compound. Colorless cubic crystals of compound **2**, found suitable for X-ray analysis, were grown in CH₂Cl₂/pet. ether at rt after standing for 24 h.

Diethylammonium 2-((2,4-dichlorophenyl)(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)methyl)-5,5-dimethyl-3-oxocyclohex-1-enolate (2c)

Compound **2c** was synthesized from dimedone and 2,4-dichlorobenzaldehyde (**1c**) as a colorless cubical crystals in CH₂Cl₂/pet. ether at rt. The crystals suitable for X-ray analysis were obtained after 3 days.

DFT calculations

In the present work, DFT calculations using the B3LYP method, together with local or non-local functionals, were performed that unites the Becke's three-parameter exchange functional (B3) with the Lee, Yang, and Parr correlation functional (LYP). The density functional theory (DFT) calculations were carried out utilizing GAMESS program. The input geometry of the synthesized compounds were optimized using at B3LYP/6-311G(d,p) basis set for C, O, N, and H atoms without imposing any external constraint on the potential energy surfaces.

Biological assay

The *p*-nitrophenyl- β -D-glucuronide (N-1627) and β -glucuronidase (E.C. 3.2.1.31, from bovine liver, G-0251) were purchased from Sigma Chemical Co. (U.S.A.). Na₂CO₃ anhydrous and all other reagents of standard grade were getting from E. Merck. The anhydrous EtOH and CHCl₃ were used in experiment and these were dried by using the standard methods. All other solvents and reagents were of standard grade like the benzoyl chloride.

β -D-glucuronidase assay

β -D-glucuronidase inhibition assay was performed as described by Khan et al. [37].

Urease assay and inhibition

The assay was performed as described by Khan et al. [38] and Weatherburn et al. [39].

Thymidine phosphorylase assay protocol

The assay was performed as described by Krenitsky et al. [40].


Cytotoxic activity

The assay was performed as described by Mosmann et al. [41].

Results and discussion

Synthesis of the salt of Michael adduct

Recently, there has been a lot of interest in the development of highly efficient transformations for the synthesis of biologically active organic molecules, with potential utilities in agrochemical or pharmaceutical industries. There is also interest in discovering new, strategically important protocols, which are efficient and environmentally benign, and lead to the complex structural variations with simple work-up procedures in high yields [32–35]. During the current study, diethylamine in aqueous medium mediated the one-pot two-component Aldol-Michael addition of 5,5-dimethylcyclohexane-1,3-dione (dimedone), with different arylaldehyde **2a–c** in 2:1 molar ratio to provide trimolecular Michael adducts **2a–c** in excellent yields up to 92 % (Scheme 1) [31].



Scheme 1 Synthetic protocol used in the present work

X-ray crystal structures

The chemical structures of the final adduct **2a–c** were unambiguously deduced by single-crystal X-ray diffraction technique (Fig. 1a–c). Tables 1, 2, 3 and 4 display the crystal data and main geometrical parameters of the compounds.

Slow evaporation of compounds **2a** (CHCl₃/Et₂O, 3 days), **2b** (DCM/pet. ether, 24 h), and **2c** (DCM/pet. ether, 2 days), at room temperature yielded pure crystals of **2a–c**. Crystals of dimensions 0.38 × 0.37 × 0.24 (**2a**), 0.47 × 0.42 × 0.14 (**2b**) and 0.31 × 0.21 × 0.20 (**2c**) mm were selected for X-ray diffraction analysis on a

Table 1 The crystal data of **2a–c**

	2a	2b	2c
Empirical formula	C ₂₇ H ₃₇ BrNO ₄	C ₂₇ H ₃₇ BrNO ₄	C ₂₇ H ₃₆ Cl ₂ NO ₄
Formula weight	519.49	519.41	509.47
Temperature	273 (2)	273 (2)	273 K
Wavelength	0.71073 Å	0.71073 Å	0.71073 Å
Crystal system	Monoclinic	Monoclinic	Monoclinic
Space group	P2 ₁ /n	P2 ₁ /c	P2 ₁ /n
A	10.2861 (11) Å	12.6829 (13) Å	10.3400 (10) Å
B	18.1701 (19) Å	12.2729 (13) Å	18.2984 (18) Å
C	15.6171 (16) Å	18.5831 (19) Å	15.0374 (15) Å
α	90°	90°	90°
β	106.5 (2)°	108.283 (3)°	98.257 (2)°
γ	90°	90°	90°
Volume	2798.5 (5) Å ³	2746.5 (5) Å ³	2815.7 (5) Å ³
Z	4	4	4
Calculated density	1.233 mgm ⁻³	1.256 mgm ⁻³	1.202 mgm ⁻³
Absorption coefficient	1.498 mm ⁻¹	1.527 mm ⁻¹	0.261 mm ⁻¹
F(000)	1092	1092	1084
Crystal size	0.38 × 0.37 × 0.24 mm	0.47 × 0.42 × 0.14 mm	0.31 × 0.21 × 0.20 mm
θ range	1.76–25.50°	1.69–25.50°	1.76–28.37°
Reflections collected	16,291	15,992	20,357
Reflections unique	5202	5050	7014
(R _{int})	0.0384	0.0597	0.0442
R ₁ with I > 2σ(I)	0.0553	0.0518	0.0605
R ₂ with I > 2σ(I)	0.1273	0.1142	0.1358
R ₁ for all data	0.1068	0.1192	0.1092
R ₂ for all data	0.1528	0.1438	0.1609
Goodness of fit	1.081	0.972	1.017
Max/min ρ e ⁻³ Å ⁻³	0.567 and -0.730	0.326 and -0.258	0.474 and -0.225
CCDC	993,141	993,142	993,140

Table 2 Geometric parameters (Å, °) of **2a** (selected)

Bond	Experimental	Calculated
Br1–C3	1.902 (4)	1.8905
O2–C13	1.286 (4)	1.2595
O4–C19	1.334 (4)	1.3831
N1–C26	1.481 (6)	1.4785
N1–C25	1.492 (6)	1.4786
C8–C13	1.388 (4)	1.3831
C14–C19	1.353 (4)	1.3558
Bond angle	Experimental	Calculated
C26–N1–C25	114.5 (4)	117.6644
O2–C13–C8	122.2 (3)	122.5294
O2–C13–C12	115.4 (3)	111.9032
O4–C19–C14	124.3 (3)	127.8520
CO4–C19–C18	110.9 (3)	113.9985
N1–C26–C27	110.3 (4)	109.9599
C24–C25–N1	111.7 (5)	111.5620

Table 3 Geometric parameters (Å, °) of **2b** (selected)


Bond	Experimental	Calculated
Br1–C2	1.897 (4)	1.8930
O1–C9	1.329 (4)	1.2650
O3–C17	1.290 (3)	1.2301
N1–C25	1.467 (4)	1.4768 s
N1–C26	1.501 (5)	1.4770
C8–C9	1.358 (4)	1.3560
C16–C17	1.386 (4)	1.3646
Bond angle	Experimental	Calculated
C25–N1–C26	112.2 (3)	117.6644
O1–C9–C8	124.6 (3)	121.5499
O1–C9–C10	111.4 (3)	119.5021
O3–C17–C16	122.6 (3)	121.3063
O3–C17–C18	116.2 (3)	111.9032
C24–C25–N1	112.8 (3)	111.5620
C27–C26–N1	111.9 (4)	109.9599

Bruker Smart Apex II diffractometer, equipped with CCD detector and graphite monochromatic MoK α radiations ($\lambda = 0.71073$ Å) at 293 (2) K. Cell refinement and data reduction were carried out by Bruker SAINT [14]. The chemical structure

Table 4 Geometric parameters (Å, °) of **2c** (selected)

Bond	Experimental	Calculated
C11–C9	1.741(2)	1.7354
C12–C11	1.736(3)	1.7207
O2–C5	1.299(2)	1.2307
O4–C19	1.329(3)	1.2639
N1–C26	1.472(4)	1.4774
N1–C25	1.482(4)	1.4775
C4–C5	1.508(3)	1.5113
C14–C19	1.360(3)	1.3646
Bond angle	Experimental	Calculated
O2–C5–C6	121.97(19)	121.9985
O2–C5–C4	115.08(18)	118.2618
O4–C19–C14	125.1(2)	120.7989
O4–C19–C18	110.92(19)	119.0782
C8–C9–C11	120.03(19)	119.9182
C11–C10–C9	118.8(2)	119.8890
C12–C11–C10	120.0(2)	120.1922
C12–C11–C12	120.1(2)	119.9325
N1–C26–C27	110.9(3)	110.2876
C24–C25–N1	112.1(3)	110.1151

was solved by using SHELXS-97 [15, 16]. The listed crystallographic parameters in Table 1 indicate that compounds **2a**, **2b**, and **2c** were crystallized in monoclinic crystal system with space group $P2_1/n$ for **2a** and **2c** and $P2_1/c$ for **2b**. The crystal structures **2a**, **2b**, and **2c** (Fig. 1a) were finally refined with R factor of 5.5, 5.1, and 6.0 %, respectively. The molecule of diethyl amine solvate played an important role to stabilize the structures in crystal lattice through intermolecular hydrogen bondings (Fig. S7–S9; Table S1–S3; see supplementary material).

**Fig. 1** The structure of **2a–c** (ORTEP diagrams)

DFT calculations

Optimized molecular geometry

From our XRD data, it is clear that compounds **2a**, **2b**, and **2c** possess monoclinic crystal structures. The cell dimensions and other data are presented in Table 1. Selected values of calculated DFT and experimental geometric parameters for the synthesized molecules were found to be in good agreement, and are listed in Tables 2, 3 and 4. Figures 2 and 3 depict the optimized structures and HOMO–LUMO for compounds **2a**, **2b**, and **2c**.




Fig. 2 Optimized molecular structures of compounds **2a**, **2b**, and **2c**




Fig. 3 HOMO and LUMO for compounds **2a**, **2b**, and **2c**

Thermal gravimetric analysis (TGA)

Thermal stability of the synthesized compounds was investigated by thermogravimetric analysis (TGA). All the samples were made under nitrogen atmosphere in the temperature ranges between 0 and 800 °C with a heating ramp rate of 10 °C per min (Table 5). It has shown that all the synthesized compounds demonstrated thermal stability up to 200 °C, with a percentage weight loss of 31.45, 22.42, and 16.12 for the compounds **2a**, **2b**, and **2c**, respectively. When the temperature was further raised to 300 °C, dramatic percentage weight loss of up to 98.9, 97.3, and 97.7 for the compounds **2a**, **2b**, and **2c** respectively. Hence, it can be said that the synthetic compounds are thermally stable up to 200 °C, and from there on a rapid degradation occur (Fig. 4).

Biological activity evaluation

Compounds **2a–c** were screened in vitro for different bio-assays such as thymidine phosphorylase, urease, and β -glucuronidase inhibition assays. These compounds

Table 5 Weight loss of synthesized molecules with temperature

Temperature	Weight loss (%)		
	2a	2b	2c
100	0.07	0.24	0
200	31.45	22.42	16.12
300	98.907	97.301	97.794
400	99.5205	98.977	98.17
500	99.8727	99.318	98.212
600	99.6842	99.621	98.045
700	99.6564	99.4393	97.682
800	99.8236	99.088	97.215

Fig. 4 The TGA curve of the studied compounds **2a**, **2b** and **2c**




Table 6 Results of biological activity of the synthesized compounds **2a–c**

Compounds	Cytotoxicity (PC-3 cell line)	Cytotoxicity (HeLa cell line)	Thymidine phosphorylase inhibition IC ₅₀ ± SEM (μM)	Urease inhibition IC ₅₀ ± SEM (μM)	β-glucuronidase inhibition IC ₅₀ ± SEM (μM)
2a	NA	NA	NA	154.8 ± 1.33	351.6 ± 4.12
2b	>30	>30	283.3 ± 0.7	75.4 ± 1.46	NA
2c	>30	>30	243.3 ± 1.5	108.2 ± 1.3	NA
Std.	Doxorubicin 0.912 ± 0.12	Doxorubicin 0.506 ± 0.15	7-Deazaxanthine 41 ± 1.64	Thiourea 21.2 ± 1.3	D-Saccharic acid 1-4 lactone 45.75 ± 2.16

were also evaluated for their cytotoxic effect against PC-3 and HeLa cell lines. Results are summarized in Table 6.

Compounds **2b**, **c** showed a varying degree of thymidine phosphorylase inhibition with IC₅₀ values 283.3 ± 0.7 and 243.3 ± 1.5 μM, respectively, against the tested standard drug 7-deazaxanthine (IC₅₀ = 41 ± 1.64 μM). Compound **2a** found to be inactive (Table 6).

The tested compound **2a–c** (IC₅₀ = 154.8 ± 1.33, 75.4 ± 1.46, and 108.2 ± 1.3 μM) showed weak urease inhibition activity against the standard compound thiourea (IC₅₀ = 21.2 ± 1.3 μM). Michael adducts **2a–c** were also evaluated for their in vitro β-glucuronidase inhibitory potential and compound **2a** (IC₅₀ = 351.6 ± 4.12 μM) showed weak inhibition of β-glucuronidase enzyme in comparison to the standard drug D-saccharic acid 1-4 lactone (IC₅₀ = 45.75 ± 2.16 μM). Michael adducts **2b** and **2c** found to be inactive.

Michael adducts **2b–c** were found to be non cytotoxic against of PC-3 normal and HeLa cancer cell lines, and showed >30 % inhibition while compound **2a** was found to be inactive against PC-3 normal and HeLa cancer cell lines (Table 6).

Conclusions

In the present study, three Michael adducts were synthesized by using a simple, high-yielding, and economical synthetic scheme. The structures were established with the help of physico-chemical properties and single-crystal X-ray diffraction technique. Single-crystal X-ray analysis and DFT calculations revealed that H-bonding plays a crucial role in stability of the molecules. It was observed that all the synthesized compounds demonstrated a thermal stability up to 200 °C. Compounds **2a–c** were also evaluated for their biological activities in various in vitro biological assays.

Acknowledgments The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding this Research group NO (RG -257-1435-1436).

References

1. M.E. Bodini, J. Pardo, V. Arancibia, Spectrophotometric determination of selenium(IV) with 5,5-dimethyl-1,3-cyclohexanedione. *Talanta* **37**, 439–442 (1990)
2. L.V. Benitez, W.S. Allison, The inactivation of the acyl phosphatase activity catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate dehydrogenase by dimedone and olefins. *J. Biol. Chem.* **249**, 6234–6243 (1974)
3. H. El Sayed, El Ashry, L.F. Awada, Y. El Kilany, E.I. Ibrahim, Dimedone: a versatile precursor for annulated heterocycles. *Adv. Heterocycl. Chem.* **98**, 1–141 (2009). **(and references therein)**
4. T. Saitoh, K. Taguchi, M. Hiraide, Derivatization of formaldehyde with dimedone and subsequent sorption on sodium dodecylsulfate/alumina admicelles for fluorometric analysis. *Anal. Sci.* **18**, 1267–1268 (2002)
5. R.J. Cremlyn, D. Saunders, Chlorosulfonation of 9-aryl 3,3,6,6-tetramethyloctahydroxanthene-1,8-diones. *Phosphorus Sulfur Silicon* **81**, 73–82 (1993)
6. J.V. Greenhill, Enaminones. *Chem. Soc. Rev.* **6**, 277–294 (1977)
7. W. Guan-Wu, M. Chun-Bao, Environmentally benign one-pot multi-component approaches to the synthesis of novel unsymmetrical 4-arylacridinediones. *Green Chem.* **8**, 1080–1085 (2006)
8. L.D. James, A.G. Richard, K. De Surya, An efficient one-pot synthesis of polyhydroquinoline derivatives through the Hantzsch four component condensation. *J. Mol. Catal. A: Chem.* **256**, 309–311 (2006)
9. K.C. Majumdar, S.K. Samanta, *Aza*- claisein rearrangement: synthesis of dimedone-annulated unusual heterocycles. *Tetrahedron* **57**, 4955–4958 (2001)
10. K.C. Majumdar, S.K. Samanta, Sulfoxide- claisein rearrangement: synthesis of dimedone-annulated unusual heterocycles. *Tetrahedron* **58**, 4551–4554 (2002)
11. E.G. Meek, J.H. Turnbull, W. Wilson, Alicyclic compounds. Part II. The preparation of cyclohexane-1: 3-diones and their enol ethers. *J. Chem. Soc.* 811–815 (1953)
12. L. Bonsignore, G. Loy, D. Secci, A. Calignano, Synthesis and pharmacological activity of 2-oxo-(2H) 1-benzopyran-3-carboxamide derivatives. *Eur. J. Med. Chem.* **28**, 517–520 (1993)
13. J.Z. Deng, D.A. Sun, S.R. Starck, S.M. Hecht, R.L. Cerny, J.R. Engen, Chrysochlamic acid, a new diterpenoid-substituted quinol from *Chrysochlamysulei* that inhibits DNA polymerase β . *J. Chem. Soc. Perkin Trans. 1*, 1147–1150 (1999)
14. R.L. Frank, H.K. Hall, Monocyclic terpenes from cyclic 1,3-diketones. *J. Chem. Soc.* **72**, 1645 (1950)
15. B.C. Pal, Dehydration of β -Phenylethylcyclohexanol-3. *J. Am. Chem. Soc.* **11**, 3397 (1955)
16. Y. Cui, Y. Dang, Y. Yang, R. Ji, Synthesis of novel oxazolidinone derivatives for antibacterial investigation. *Curr. Sci.* **83**, 531 (2005)
17. H. Jae-Min, Y. Sung-Ho, J. Kang-yeoun, Synthesis of oxazolidinone phosphonate derivatives, part II. *Bull. Korean Chem. Soc.* **28**, 821–826 (2007)
18. Y.W. Jo, W.B. Im, J.K. Rhee, M.J. Shim, W.B. Kim, E.C. Choi, Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring. *Bioorg. Med. Chem.* **12**, 5909–5915 (2004)
19. A.N. Pae, H.Y. Kim, H.J. Joo, B.H. Kim, Y.S. Cho, K.I. Choi, J.H. Choi, H.Y. Koh, Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles. *Bioorg. Med. Chem. Lett.* **9**(18), 2679–2684 (1999)
20. A. Banerjee, A.K. Mukherjee, Chemical aspects of santalin as a histological stain. *Stain Technol.* **56**, 83–85 (1981)
21. S.M. Menchen, S.C. Benson, J.Y.L. Lam, W. Zhen, D. Sun, B.B. Rosenblum, S.H. Khan, M. Taing, US Patent 6, 168(2003)
22. M. Ahmad, T.A. King, D.K. Ko, B.H. Cha, J. Lee, Performance and photostability of xanthene and pyrromethene laser dyes in sol-gel phases. *J. Phys. D Appl. Phys.* **35**, 1473 (2002)
23. C.G. Knight, T. Stephens, Xanthene-dye-labelled phosphatidylethanolamines as probes of interfacial pH. Studies in phospholipid vesicles. *Biochem. J.* **258**, 683–687 (1989)
24. T. Hideo, J. Teruomi, (Sankyo Co.) Benzopyrano[2,3-b]xanthene derivatives and its preparation, *Jpn. Patent* 56005480 (1981)
25. J.P. Poupelin, G. Saint-Ruf, O. Foussard-Blanpin, G. Marcisse, G. Uchida-Ernouf, R. Lacroix, Synthesis and antiinflammatory properties of bis(2-hydroxy-1-naphthyl)methane derivatives. I monosubstituted derivatives. *Eur. J. Med. Chem.* **13**, 67–71 (1978)

26. R.W. Lambert, J.A. Martin, J.H. Merrett, K.E.B. Parkes, G.J. Thomas, Pyrimidine nucleosides, PCT Int. Appl. WO9706178, (1997)
27. C.D. Dewse, C.G. Potter, Inhibitory effect of phenylbutazone and oxyphenbutazone on DNA synthesis in normal human bone marrow cells in vitro. *J. Pharm. Pharmacol.* **27**, 523–526 (1975)
28. A. Ramazani, A. Rezaei, Novel one-pot, four-component condensation reaction: an efficient approach for the synthesis of 2,5-disubstituted 1,3,4-oxadiazole derivatives by a Ugi-4CR/*aza*-wittig sequence. *Org. Lett.* **12**, 2852–2855 (2010)
29. A. Ramazani, Z. Karimi, A. Souldozi, Y. Ahmadi, Four-component synthesis of 1,3,4-oxadiazole derivatives from *N*-isocyaniminotriphenylphosphorane, aromatic carboxylic acids, aromatic bis-aldehydes, and secondary amines. *Turk. J. Chem.* **36**, 81–91 (2012)
30. A. Ramazani, M. Rouhani, A. Rezaei, N. Shajari, A. Souldozi, The reaction of (*N*-Isocyanimino)triphenylphosphorane with biacetyl in the presence of aromatic carboxylic acids: efficient one-pot three-component reaction for the synthesis of 3-(5-Aryl-1,3,4-oxadiazol-2-yl)-3-hydroxybutan-2-one derivatives. *Helv. Chim. Acta* **94**, 282–289 (2011)
31. A.M. Al-Majid, M.S. Islam, A. Barakat, N.J. Al-Qahtani, S. Yousuf, M.I. Choudhary, Tandem Knoevenagel–Michael reactions in aqueous diethylamine medium: a greener and efficient approach toward bis-dimedone derivatives. *Arab. J. Chem.* (2014). doi:10.1016/j.arabjc.2014.04.008
32. A. Barakat, A.M. Al-Majid, A.M. Al-Ghamdi, Y.N. Mabkhot, M.R. Siddiqui, H.A. Ghabbour, H.-K. Fun, Tandem Aldol–Michael reactions in aqueous diethylamine medium: a greener and efficient approach to dimedone-barbituric acid derivatives. *Chem. Cent. J.* **8**, 9 (2014)
33. A. Barakat, A.M. Al-Majid, H.J. AL-Najjar, Y.N. Mabkhot, H.A. Ghabbour, H.-K. Fun, *RSC Advances* **4**, 4909 (2013)
34. H.J. Al-Najjar, A. Barakat, A.M. Al-Majid, Y.N. Mabkhot, H.A. Ghabbour, H.-K. Fun, A greener, efficient approach to Michael addition of barbituric acid to nitroalkene in aqueous diethylamine medium. *Molecules* **19**, 1150–1162 (2014)
35. A.M. Al-Majid, A. Barakat, H.J. Al-Najjar, Y.N. Mabkhot, H.A. Ghabbour, H.-K. Fun, Tandem Aldol–Michael reactions in aqueous diethylamine medium: a greener and efficient approach to bis-pyrimidine derivatives. *Int. J. Mol. Sci.* **14**, 23762–23773 (2013)
36. A. Barakat, M.S. Islam, A.M. Al-Majid, Z.A. Al-Othman, Highly enantioselective Friedel–Crafts alkylation of indoles with α , β -unsaturated ketones with simple Cu(II)-oxazoline-imidazoline catalysts. *Tetrahedron* **69**, 5185–5192 (2013)
37. K.M. Khan, S. Shujaat, S. Rahat, S. Hayat, Atta-ur-Rahman, M.I. Choudhary, β -N-cyanoethyl acyl hydrazide derivatives: a new class of β -glucuronidase inhibitors. *Chem. Pharm. Bull. (Tokyo)* **50**(11), 1443–1446 (2002)
38. K.M. Khan, S. Iqbal, M.A. Lodhi, G.M. Maharvi, Zia-Ullah, M.I. Choudhary, Ur. R. Atta, S. Perveen, *Bioorg. Med. Chem.*, **12**, 1963–1968 (2004)
39. M.W. Weatherburn, *Anal. Chem.* **39**, 971 (1967)
40. T.A. Krenitsky, S.R.M. Bushby, U.S. Patent, 4, 178,212, 1–8, Burroughs Wellcome Co., Research Triangle Park, NC, (1979)
41. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays “*Journal of Immunological. Methods* **65**, 55–63 (1983)